uprifosbuvir
Small moleculeexperimental
Uprifosbuvir (MK-3682) is an antiviral drug developed for the treatment of hepatitis C. It is a nucleotide analogue which acts as an NS5B RNA polymerase inhibitor. As of 2019 it was in Phase III human clinical trials. — Wikipedia
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2013 (NCT01974687)
Timeline
Indications
Mechanism of action
- RNA-directed RNA polymeraseINHIBITOR
RNA-directed RNA polymerase inhibitor
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)OC(=O)[C@@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(Cl)[C@@H]1O)Oc1ccccc1- Mol. weight
- 545.91 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL3833371 ↗
- WikipediaUprifosbuvir ↗
Also known as
- mk-3682
- mk-3682
- uprifosbuvir
- uprifosbuvir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02956629 | Phase 2 | Nov 16, 2016 | Merck |
| NCT02759315 | Phase 2 | May 3, 2016 | Merck |
| NCT02666352 | Phase 1 | Jan 22, 2016 | Merck |
| NCT02661126 | Phase 1 | Jan 1, 2016 | Merck |
| NCT02613403 | Phase 2 | Dec 10, 2015 | Merck |
| NCT02332720 | Phase 2 | Jan 28, 2015 | Merck |
| NCT02332707 | Phase 2 | Jan 22, 2015 | Merck |
| NCT01974687 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2013 | Merck |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 8 | 8 | 2 | 2013 |
1 organizations
Page 1 / 1